Flibanserin

Catalog No.S3716 Synonyms: BIMT-17, BIMT-17-BS

For research use only.

Flibanserin (BIMT-17, BIMT-17-BS) is a nonhormonal, centrally acting molecule that acts as an agonist at postsynaptic 5-HT1A receptors and as an antagonist at 5-HT2A receptors.

Flibanserin Chemical Structure

CAS No. 167933-07-5

Selleck's Flibanserin has been cited by 1 Publication

Purity & Quality Control

Choose Selective 5-HT Receptor Inhibitors

Other 5-HT Receptor Products

Biological Activity

Description Flibanserin (BIMT-17, BIMT-17-BS) is a nonhormonal, centrally acting molecule that acts as an agonist at postsynaptic 5-HT1A receptors and as an antagonist at 5-HT2A receptors.
Targets
5-HT1A [2]
(CHO)
D4 receptor [2]
(CHO)
5-HT2A [2]
(CHO)
1 nM(Ki) 4-24 nM(Ki) 49 nM(Ki)
In vitro

Flibanserin has preferential affinity for serotonin 5-HT1A, dopamine D4, and serotonin 5-HT2A receptors. In vitro and in microiontophoresis, flibanserin behaves as a 5-HT1A agonist, a very weak partial agonist on dopamine D4 receptors, and a 5-HT2A antagonist. Flibanserin also shows some affinity for human D2L and D3 receptors and rat NE-alpha 1 and 5-HT7 receptors. Flibanserin has different affinity for rat (> 10,000 nM) and human (305-785 nM) D2 receptors. The affinity for all other receptors, including the 5-HT transporter, varies from low to very low[2]. In vitro studies showed that flibanserin reduced forskolin-stimulated cAMP formation in cells and rat tissues and antagonized the accumulation of phosphatidyl inositol turnover induced by 5-HT in the mouse cortex[3].

In vivo In vivo flibanserin binds equally to 5-HT1A and 5-HT2A receptors[2]. In rats, flibanserin administration has been shown to lead to brain region-specific decreases in serotonin (5-HT) and increases in dopamine and norepinephrine. Flibanserin exposure is proportional to dose. The plasma protein binding of flibanserin (98% to albumin) is high. Flibanserin administration leads to brain region-specific increases in dopamine and norepinephrine (which are involved in the ‘excitement’ phase of the sexual response) and decreases in serotonin (5-HT) (which is involved in the ‘inhibitory’ phase). The absolute bioavailability of flibanserin after oral administration is 33.2%, and it is moderately distributed in body tissues, with a half-life of about 10 h. Steady state is established within 3 days. Flibanserin is well-tolerated at doses up to 100 mg/day (the highest dose tested in PhaseIII) for 24 weeks[1].

Protocol (from reference)

Animal Research:[3]
  • Animal Models: Sprague-Dawley rats
  • Dosages: 3 and 10 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

DMSO 78 mg/mL
(199.79 mM)
Ethanol 23 mg/mL
(58.91 mM)
Water Insoluble

Chemical Information

Molecular Weight 390.40
Formula

C20H21F3N4O

CAS No. 167933-07-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03707340 Recruiting Drug: Flibanserin Pill Breast Cancer|Hyposexual Desire Disorder Memorial Sloan Kettering Cancer Center September 14 2018 --
NCT01188603 Completed Drug: flibanserin 100 mg dose every evening Sexual Dysfunctions Psychological Sprout Pharmaceuticals Inc July 2010 Phase 1
NCT00277914 Completed Drug: Flibanserin Sexual Dysfunctions Psychological Sprout Pharmaceuticals Inc January 2006 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Flibanserin | Flibanserin ic50 | Flibanserin price | Flibanserin cost | Flibanserin solubility dmso | Flibanserin purchase | Flibanserin manufacturer | Flibanserin research buy | Flibanserin order | Flibanserin mouse | Flibanserin chemical structure | Flibanserin mw | Flibanserin molecular weight | Flibanserin datasheet | Flibanserin supplier | Flibanserin in vitro | Flibanserin cell line | Flibanserin concentration | Flibanserin nmr